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Introduction 
Sorafenib inhibits a variety of tyrosine kinase 
receptors responsible for tumor cell proliferation and 
angiogenesis. The medication has been approved for 
the treatment of advanced hepatocellular carcinoma 
and renal cell carcinoma but has also been shown to 
be effective in treating various other cancers 
including thyroid cancer [1]. Adverse cutaneous 
reactions occur in nearly 90% of sorafenib treated 
patients [2]. As both the antitumor efficacy and 
incidence of skin toxicity of sorafenib are dose 
dependent, the development of skin toxicity 
parallels the antitumor effectiveness of the 
medication [3]. 
The most frequent adverse cutaneous reaction is a 
hand-foot-skin reaction, which has been reported in 
different series to occur in 21%-93% of patients on 
sorafenib [2, 4]. Other cutaneous reactions include 
the development of an erythematous rash on the 
scalp and face occurring in 63% of patients, 
subungual splinter hemorrhages (70%), scalp 
dysesthesia (49%), alopecia (4%-57%), pruritus (4%-
32%), xerosis (6%-27%), and skin follicular 
hyperkeratosis (21%), [2, 4]. Reports of less common 
cutaneous reactions have included skin neoplasms, 
areolar hyperkeratosis, eruptive nevi, and 
psoriasiform rashes [4]. Herein, we present a patient 
that developed hidradenitis suppurativa (HS) after 
initiation of sorafenib. 
 
Case Synopsis 
A 33-year-old man on sorafenib for papillary thyroid 
cancer presented for evaluation of “boils” that began 
when he initiated chemotherapy 5 years prior and 
had continued to progress. The patient denied a 
history of similar lesions prior to the onset of 
sorafenib. Examination revealed multiple 
erythematous, violaceous papules and pustules, as 
well as draining sinus tracts in the bilateral axillae 
and inguinal region, consistent with HS (Figure 1). 
He was treated with doxycycline and hydrocortisone 
2.5% cream and treatment with sorafenib was held. 
After the sorafenib was discontinued, the patient 
noted marked improvement in his lesions and after a 
month stopped treatment with doxycycline and 
hydrocortisone. The patient’s HS continued to 
improve on the chemotherapy drug holiday despite 
no ongoing topical treatment. Six months after 
discontinuing sorafenib, no axillary sinus tracts 
remained and only mild scarring was noted. 
Abstract 
Sorafenib is a multi-kinase inhibitor approved for the 
treatment of renal cell and hepatocellular carcinoma. 
Adverse cutaneous reactions are a very common side 
effect of the medication. We report the development 
of hidradenitis suppurativa (HS) in a patient after 
initiation of treatment with sorafenib. HS is marked 
by recurrent deep painful nodules, fluctuant 
abscesses, and draining sinus tracts most frequently 
occurring in the groin and axilla. To our knowledge, 
sorafenib-induced HS in the axillary and inguinal skin 
folds has not been previously reported. 
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Case Discussion 
The clear temporal association between the 
development of HS lesions upon sorafenib initiation 
and the improvement upon cessation of the drug, 
suggests that our patient’s HS was triggered by 
sorafenib. Classic HS within the skin folds of the axilla 
and groin has not been previously associated with 
sorafenib. Pichler et al., reported a case of an acne 
inversa-like lesion on the leg after initiation of 
sorafenib, which improved with lowering the dose of 
sorafenib in combination with topical antibiotics [5]. 
Although the lesion reported by Pichler et al. was 
considered to be acne inversa-like, we describe a 
presentation that matches the characteristic 
description of HS with abscesses and draining sinus 
tracts in the axilla and groin. 
The mechanisms behind sorafenib-induced 
cutaneous toxicities remain unclear but have been 
associated with blockade of PDGF and KIT in the  
eccrine gland epithelium and antagonism of VEGFRs 
in subcutaneous vessels, which may lead to impaired 
cutaneous regeneration and healing [2]. 
Hyperkeratinization of the follicle infundibulum is 
believed to play a central role [6]. A study by Frank et 
al. found that out of 43 patients on sorafenib, 9 (21%) 
developed spiny 1mm papules on the face, scalp, 
and trunk, which they termed as “spiny follicular 
hyperkeratosis [7]. Histologic examination of these 
lesions revealed an infundibulum filled with an 
orthoparakeratotic column, which extended above 
the epidermal surface [7].  
Sorafenib has been shown to cause alterations in the 
keratinocyte differentiation and proliferation 
pathways and has been associated with cyst 
formation [8]. Cases of follicular hyperplasia [9], 
perforating folliculitis [10-12], a keratosis pilaris-like 
reaction [13], and a nodular cystic eruption [14] have 
also been reported. Interestingly, sorafenib induced 
keratinocyte proliferation and follicular cyst 
formation have been linked to paradoxical activation 
of the MAP kinase pathway [8]. It is likely that the 
keratinocyte proliferating effects of sorafenib 
contributed to the development of the follicular 
cystic lesions in our patient. 
 
Conclusion 
To our knowledge this is first description of sorafenib 
associated HS in the axillary and inguinal skin folds. 
We encourage clinicians to be aware of the potential 
correlation between sorafenib and HS and 
recommend further studies to explore this 
association. Awareness of this association between 
sorafenib and HS will expediate future diagnosis and 
management. 
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Figure 1.  A) Right axillary nodules, abscesses, and sinus tract.  B) 
Left axillary nodules, abscesses, and sinus tract formation. 
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